National Institute of Dental and Craniofacial Research

ATCC Appoints Dr. Alfredo Molinolo to Its Board of Directors

Retrieved on: 
Thursday, November 2, 2023
Science, Stem Cells, Biotechnology, Research, Oncology, Health, Infectious Diseases, Genetics, Moores Cancer Center, Biorepository, DVM, Faculty of Medical Sciences, University of Buenos Aires, Head, Publication, Doctor of Philosophy, National Institute of Dental and Craniofacial Research, Hospital Rivadavia, HNSCC, Mouse Models of Human Cancer database, Medicine, Breast cancer, Medical research, University, University of California, San Diego, Collection, Breast, Bangladesh Technical Education Board, Neck, Management, Pathology, ATCC, MD, Biology, Cancer

“Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.

Key Points: 
  • “Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.
  • Dr. Molinolo earned both his PhD in oncology and MD in medicine from the University of Buenos Aires in Argentina.
  • Dr. Molinolo has received several awards and has written numerous publications about breast, oral, and head and neck cancer.
  • “Serving on the Board is an opportunity for me to make further contributions to science,” said Dr. Molinolo.

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Retrieved on: 
Tuesday, October 10, 2023
Annual general meeting, Calcium, Partnership, Walking, Cancer, Urine, Hypocalcemia, Research, PTH, The New England Journal of Medicine, Standard of care, Kidney failure, Society, American Society for Bone and Mineral Research, National Institute of Dental and Craniofacial Research, Vitamin D, Craniofacial, Kidney, Parathyroid hormone, Hypercalciuria, Hypercalcaemia, Bangladesh Technical Education Board, Blood, Endocrine Society, Patient, Quality of life, NIH, PALO, Pharmaceutical industry, Dietary supplement

“Conventional therapy for ADH1 includes raising the blood calcium levels with calcium supplements and activated vitamin D, taken in multiple doses throughout day.

Key Points: 
  • “Conventional therapy for ADH1 includes raising the blood calcium levels with calcium supplements and activated vitamin D, taken in multiple doses throughout day.
  • But this burdensome regimen may also increase urine calcium levels above normal, which can damage the kidney, leading to kidney failure in worst-case scenarios.
  • People with ADH1 need better treatments, so they are not constantly walking on a tightrope.
  • As part of the Phase 2b study, participants completed one or two 5-day inpatient dose-ranging periods, followed by a 24-week outpatient period.

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product

Retrieved on: 
Wednesday, June 7, 2023
Health, Medical Devices, Dental, Clinical Trials, Research, Science, Biotechnology, Maintenance, Extraction (chemistry), Surgeon, University, Osteoporosis, Tooth, SBIR, University of Pennsylvania School of Dental Medicine, Porosity, Multimedia, Doctor of Philosophy, Bangladesh Technical Education Board, Regenerative medicine, National Institute of Dental and Craniofacial Research, Membrane, DMD, Patient, NIDCR, Engineering, Dentistry, IDE, FDA, All India Mahila Congress, NIH, Safety

This funding ( 1R44DE032564-01 ) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development.

Key Points: 
  • This funding ( 1R44DE032564-01 ) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development.
  • These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases.
  • These procedures increase the width and height of the residual jawbone to replace atrophied bone so that a dental implant can be successfully placed.
  • This product compliments RevBio’s existing clinical program to treat the larger population of patients who need an immediate dental implant following tooth extraction.

Amend Surgical Receives Funding for Suture-less Nerve Repair Device

Retrieved on: 
Tuesday, April 11, 2023
SpaceTEC National Resource Center for Aerospace Technical Education, Tissue, Partnership, Commercialization, Connective tissue, University, Nerve, Marketing, Harvard University, Elective surgery, ITP, Spine, DOC, Research, Private practice, Sympathetic nervous system, Bangladesh Technical Education Board, Regenerative medicine, National Institute of Dental and Craniofacial Research, Regeneration, Motion, Wyss Institute, NIDCR, Collagen, OEM, FDA, Trauma, Wyss Institute for Biologically Inspired Engineering, Pharmaceutical industry, Dentistry

ALACHUA, Fla., April 11, 2023 /PRNewswire/ -- Amend Surgical, Inc., an Alachua-based medical device company, announced today that it has been awarded a substantial product development funding from The Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center to commercialize a novel, suture-less solution for the repair of peripheral nerves. Tissure is a resorbable hydrogel membrane with a chitosan-based adhesive that has the adhesion and mechanical strength to potentially replace suture for the repair of peripheral nerve injuries. Tissure is easy to apply and will greatly simplify this challenging surgical procedure. Amend Surgical exclusively licensed the rights for this technology from the Wyss Institute at Harvard University in 2020.

Key Points: 
  • Amend Surgical exclusively licensed the rights for this technology from the Wyss Institute at Harvard University in 2020.
  • The use of suture to repair peripheral nerve injuries is the current standard of care.
  • Eliminating suture for peripheral nerve repair avoids this trauma, can decrease intervening scar tissue, and protect the repair site.
  • Amend Surgical currently has nine employees and occupies a manufacturing and administrative space in the biotech corridor of Alachua, Florida.

Sinopia Awarded Grant from National Institute of Dental and Craniofacial Research for Oral Mucositis

Retrieved on: 
Thursday, February 23, 2023
Technology, Biotechnology, FDA, Health, Radiology, Oncology, Other Science, Research, Software, General Health, Health Technology, Science, Data Management, Clinical Trials, Discover, Overalls, National Institute of Dental and Craniofacial Research, Prognosis, Patient, Inflammation, Learning health systems, Therapy, Ulcer, Machine learning, Head, Bangladesh Technical Education Board, Radiation, NIDCR, Pharmaceutical industry, Dentistry, Mucositis

Sinopia Biosciences, Inc. , a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, has been awarded a grant from the National Institute of Dental and Craniofacial Research (NIDCR), a branch of the U.S. National Institutes of Health, to fund the continued evaluation of therapeutic candidates to treat oral mucositis.

Key Points: 
  • Sinopia Biosciences, Inc. , a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, has been awarded a grant from the National Institute of Dental and Craniofacial Research (NIDCR), a branch of the U.S. National Institutes of Health, to fund the continued evaluation of therapeutic candidates to treat oral mucositis.
  • Mucositis is a debilitating side effect of chemotherapy and radiotherapy that is characterized by inflammation and ulceration in mucosal tissue.
  • “When mucositis presents itself in cancer clinical care, there can be a delay in antineoplastic treatment for high-grade mucositis management that can lead to worse overall prognosis and significantly higher healthcare costs.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station

Retrieved on: 
Friday, December 9, 2022
Science, Health, Research, Medical Devices, Faculty, Periodontology, Journal of Indian Society of Pedodontics and Preventive Dentistry, National Institute of Dental and Craniofacial Research, Commercial Resupply Services, McGowan Institute for Regenerative Medicine, Doctor of Philosophy, ISS National Lab, ISS, SpaceX, Patient, National Institute on Aging, Research, Scientific research on the International Space Station, SpaceX CRS-26, CASIS, International Space Station, Bone, Histology, Condition, Tomography, University, Boeing, Multimedia, Regenerative medicine, MassChallenge, ISSNL, Osteoporosis, Micro-g environment, National Institute of Neurological Disorders and Stroke, DDS, Associate, Pharmaceutical industry, Science, Stroke

RevBio, Inc., announced that an experiment to study Tetranite, the companys regenerative bone adhesive biomaterial, has successfully been initiated onboard the International Space Station (ISS).

Key Points: 
  • RevBio, Inc., announced that an experiment to study Tetranite, the companys regenerative bone adhesive biomaterial, has successfully been initiated onboard the International Space Station (ISS).
  • On Saturday, November 26, 2022, the study materials were launched to the space station on SpaceXs 26th Commercial Resupply Services (SpaceX CRS-26) mission , sponsored by the ISS National Laboratory.
  • View the full release here: https://www.businesswire.com/news/home/20221201005635/en/
    RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station.
  • Dr. Intini and RevBio are expected to publish the complete results of the experiment by the end of next year.

Kovina Therapeutics Receives NIH Grant to Develop Human Papillomavirus E6 Inhibitors to Treat Oropharyngeal Cancers

Retrieved on: 
Tuesday, November 1, 2022
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Survival, CEO, Human papillomavirus infection, HPV-positive oropharyngeal cancer, Research, National Institute of Dental and Craniofacial Research, National Institute, NIH, Disease, Head, HPV, Oropharyngeal cancer, Incidence, NIDCR, Cancer, Therapy, Profile, SBIR, CSO, Biotechnology, Science, Small Business Innovation Research, Pharmaceutical industry, Vaccine

Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH) to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections.

Key Points: 
  • Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH) to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections.
  • Oropharyngeal cancers arising from HPV infections are increasing across many age groups and around the world.
  • This SBIR grant funds testing of our novel HPV inhibitory compounds for activity in preclinical models of oropharyngeal cancer.
  • Kovina Therapeutics is a biotechnology company developing first-in-class antiviral therapies to treat cancers and premalignant infections caused by Human Papillomavirus (HPV).

TOMI Environmental Receives Order From National Institutes of Health (NIH); TOMI Products Now Deployed in Over 20 NIH Facilities Across 11 Divisions

Retrieved on: 
Thursday, October 20, 2022
Hydrogen, National Institute, U.S. Department of Defense Strategy for Operating in Cyberspace, NIEHS, Hydrogen peroxide, SEC, Government, Corrosion, Infection, VRC, IHP, National Institute of Dental and Craniofacial Research, Biosafety, NASDAQ, Annual report, COO, Restaurant, Decontamination, Hospital, Vaccine Research Center, HHS, Research, NIH, NIAID, DARPA, Police, National Institute of Environmental Health Sciences, Technology, Allergy, National Cancer Institute, RML, Rocky Mountain Laboratories, Disinfectant, Association, GLOBE, Office of Inspector General, U.S. Department of Health and Human Services, EPA, Forward-looking statement, COVID-19, NIDCR, Meat, School, NCI, Pharmaceutical industry

This purchase order reflects their continued implementation of SteraMist iHP technology within decontamination protocols to improve sterility and facility productivity.

Key Points: 
  • This purchase order reflects their continued implementation of SteraMist iHP technology within decontamination protocols to improve sterility and facility productivity.
  • In total, NIH has deployed approximately thirty (30) SteraMist machines across eleven (11) divisions, including National Institute of Allergy & Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS), National Institute of Dental and Craniofacial Research (NIDCR), National Cancer Institute (NCI), Vaccine Research Center (VRC), and Rocky Mountain Laboratories (RML).
  • Shane, COO of TOMI, states, SteraMist is used throughout many government agencies, and we take pride in supporting customers like NIH.
  • These forward-looking statements include, without limitation, statements relating to TOMIs ability to develop products for NIH and government use.

Main Line Health scientist attracts $1M gift to advance revolutionary research into scarless healing--even for age-associated chronic wounds

Retrieved on: 
Thursday, September 15, 2022
Adult, Institute, Chicago Tribune, Regenerative medicine, University of California, Berkeley, Human, Department, Murphy Roths large, Research, Chicago, National Institute of Dental and Craniofacial Research, Starfish, View, Mouse, Regeneration, London, Scar, Bone loss, Terminator, Medical research, Ellen Heber-Katz, B cell, Daniel B. Ginsberg, Doctor of Philosophy, The Sunday Times, Main Line Health, Lankenau Institute for Medical Research, Department of Defense Serum Repository, Skin, Multimedia, University, Craniofacial, Amphibian, MRL, Patent, Periodontal disease, National Institute, Pharmaceutical industry, Trapping, The New York Times

MERION STATION, Pa., Sept. 15, 2022 /PRNewswire/ -- Scientists had thought only starfish and amphibians like frogs and salamanders could heal wounds in a way that looked as if the injury never occurred, even regenerating entire limbs. Mammals—including humans—had lost the ability to generate new tissue to evolution.

Key Points: 
  • Her mid-1990s discovery not only sparked hope for human scarless healing but triggered headlines worldwide.
  • Dr. Heber-Katz was named inaugural chairholder of The Daniel B. and Florence E. Green Endowed Chair in Regenerative Medicine Research last night.
  • "This gift will accelerate the timetable for testing in humans and, I firmly believe, bring a drug to market," Dr. Heber-Katz said.
  • Dr. Heber-Katz has two key products near the stage for human testing:
    A drug in the form of a hydrogel.

National Institute of Health (NIH) awards Matregenix a Phase 1 SBIR grant to develop a new dental barrier membrane for guided bone regeneration

Retrieved on: 
Friday, September 2, 2022
Connective tissue, National Institute of Dental and Craniofacial Research, University, CEO, National Institute, Research, Octane, University of Michigan School of Dentistry, Dental, Regeneration, BARDA, Biomedical Advanced Research and Development Authority, NIH, GBR, National, National Institutes of Health, SBIR, Small Business Innovation Research, Growth, Development, Patient, Pharmaceutical industry, Medical device

IRVINE, Calif., Sept. 1, 2022 /PRNewswire/ -- Matregenix announces a grant award from the National Institute of Dental & Craniofacial Research under the auspices of the Small Business Innovation Research (SBIR) program and National Institutes of Health (NIH). The grant will be utilized to develop a new dental barrier membrane for guided bone regeneration.

Key Points: 
  • IRVINE, Calif., Sept. 1, 2022 /PRNewswire/ -- Matregenix announces a grant award from the National Institute of Dental & Craniofacial Research under the auspices of the Small Business Innovation Research (SBIR) program and National Institutes of Health (NIH).
  • The grant will be utilized to develop a new dental barrier membrane for guided bone regeneration.
  • Guided bone regeneration (GBR) is a common technique used in the dental industry for the treatment of bony defects, among other conditions.
  • In addition, the Matregenix Transparent Nanofiber Mask was announced as a Phase 2 finalist in the Biomedical Advanced Research and Development Authority (BARDA)-NIOSH-NIST Mask Innovation Challenge.